We found that AKR7A3 overexpressed cells have lower c-Jun and NF-κB activities, which could explain our data of AKR7A3 antagonizing cell growth and sensitizing HCC cells to chemotherapy drugs. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.